{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000086","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.114306+00:00","generated_at":"2026-05-17T00:12:51.857803+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies","bullets":["Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.","Cash $633.9M at Sept 30, 2025; expects year-end cash $570-590M and runway into 2028.","XmAb819 (ccRCC) and XmAb541 (gynecologic/germ cell) show early PRs; Phase 3 dose selection in 2026; pivotal studies targeted for 2027.","First patient dosed in plamotamab Phase 1b RA study; XmAb942 Phase 2b XENITH-UC enrolling; XmAb657 and XmAb412 studies on track.","Partners advancing: Amgen Phase 3 XALience for xaluritamig; Astellas data on ASP2138; Zenas positive Phase 2 in MS."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000086","json":"https://secwatch.observer/filing/0001326732-25-000086.json","markdown":"https://secwatch.observer/filing/0001326732-25-000086.md","text":"https://secwatch.observer/filing/0001326732-25-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/0001326732-25-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/xncr-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:12:51.857803+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}